Michel Brousset - 30 Jul 2026 Form 4 Insider Report for Waldencast plc (WALD)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: WALD
Reported as of: 30 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 16:10:59 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Michel Brousset

Key filing fact

Michel Brousset filed Form 4 for Waldencast plc (WALD) on 07 Aug 2026.

Key facts

This page summarizes Michel Brousset's Form 4 filing for Waldencast plc (WALD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2026, 16:10.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001841075 Primary reporting owner

Brousset Michel

Relationship: Chief Executive Officer, Director
Address: C/O WALDENCAST PLC, MICHELIN HOUSE, 81 FULHAM ROAD, LONDON, UNITED KINGDOM
Signature: /s/ Michel Brousset
Signature date: 07 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WALD transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -264,294
Change %: -100%
Price: $2.00^*
Shares after: 0
Date: 30 Jul 2026
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 264,294
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Michel Brousset is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.

Footnote F2

Represents the Issuer's purchase of 264,294 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.

Footnote F3

On October 30, 2024, the reporting person was granted 396,440 RSUs, which would have vested over a three-year period as follows: (i) 132,146 on October 1, 2025; (ii) 132,147 on October 1, 2026; and (iii) 132,147 on October 1, 2027.